Nasal Spray Desmopressin (DDAVP) for Mild Hemophilia A and von Willebrand Disease
- 1 April 1991
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 114 (7) , 563-568
- https://doi.org/10.7326/0003-4819-114-7-563
Abstract
Objective: To evaluate the effect of a nasal spray preparation of desmopressin (DDAVP) on levels of factor VIII activity, ristocetin cofactor activity, and von Willebrand antigen as well as the length of bleeding time in patients with mild hemophilia A and von Willebrand disease; to determine whether effective hemostatic levels can be attained; and to compare the effect of this spray with that of standard intravenous desmopressin treatment. Design: Before-and-after trial in patients known to respond to intravenous desmopressin. Setting: Regional, comprehensive, hemophilia diagnosis and treatment center. Patients: A total of 22 patients, including 11 patients with von Willebrand disease, 8 patients with mild hemophilia A, and 3 symptomatic hemophilia carriers. Interventions: Patients were infused with desmopressin, 0.3 μg/kg body weight. At least 1 week later, they were taught to self-administer desmopressin nasal spray, 150 μg to each nostril. Measurements: In patients with hemophilia, the level of factor VIII activity was measured; in patients with von Willebrand disease, levels of factor VIII activity, ristocetin cofactor activity, and von Willebrand antigen as well as bleeding time were measured before and after each administration of desmopressin. Main Results: Desmopressin, when administered intravenously or intranasally, elevated levels of factor VIII, ristocetin cofactor, and von Willebrand antigen in both mildly hemophiliac patients and patients with von Willebrand disease when compared with baseline measures (P < 0.05). Factor VIII levels adequate for hemostasis were achieved by 82% of the hemophiliac patients. An abnormal bleeding time was corrected in the majority (62%) of patients with von Willebrand disease. Conclusion: A nasal spray preparation of desmopressin apparently was effective both in treating bleeding episodes and when used prophylactically for minor surgical procedures in several patients.Keywords
This publication has 14 references indexed in Scilit:
- Evaluation of the effectiveness of DDAVP in surgery and in bleeding episodes in haemophilia and von Willebrand's disease. A study on 43 patientsClinical and Laboratory Haematology, 2008
- Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type IAnnals of Hematology, 1990
- Hyponatremia and seizures in young children given ddavpAmerican Journal of Hematology, 1989
- Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasisThe Journal of Pediatrics, 1989
- Effects of Concentration and Volume on Nasal Bioavailability and Biological Response to DesmopressinJournal of Pharmaceutical Sciences, 1988
- Intranasal Administration of Peptides: Nasal Deposition, Biological Response, and Absorption of DesmopressinJournal of Pharmaceutical Sciences, 1986
- Response of Patients with Mild and Moderate Hemophilia A and von Willebrand's Disease to Treatment with DesmopressinAnnals of Internal Medicine, 1985
- The subcutaneous administration of the vasopressin analogue 1-desamino-8-D-arginine vasopressin in patients with von Willebrand's disease and hemophiliaJournal of Molecular Medicine, 1984
- DDAVP: A useful alternative to blood components in moderate hemophilia A and von Willebrand diseaseThe Journal of Pediatrics, 1983
- 1-DEAMINO-8-D-ARGININE VASOPRESSIN: A NEW PHARMACOLOGICAL APPROACH TO THE MANAGEMENT OF HAEMOPHILIA AND VON WILLEBRAND'S DISEASEThe Lancet, 1977